SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 144 participants.

Also called NCT07614230

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 144 participants (planned count) (from the registry)
Sponsor
Junjie Yang (from the registry)
Registry
  • NCT NCT07614230
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07614230. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2027-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes
Acronym
SCOPE
Condition
Type 2 Diabetes Mellitus (T2DM)
Condition
Atherosclerosis
Intervention (Drug)
Dapagliflozin (DAPA)
Intervention (Other)
Standard Care (Treatment as Usual)
Lead sponsor
Junjie Yang (class: other)

Record details

Record id
cardio:ct-nct07614230
Content hash
1fe44020515392eb808e4a4ddf3ce6017caf2642a4f4582429577e3abef58862